RESUMEN
OBJECTIVES: To characterize the gut hormone profile and determine the effect of satiety gut hormone blockade on food intake in disease-free postesophagectomy patients. BACKGROUND: Improved oncologic outcomes for esophageal cancer have resulted in increased survivorship and a focus on health-related quality of life. Anorexia and early satiety are common, but putative causative factors, in particular the gut-brain hormonal axis, have not been systematically studied. METHODS: In a double-blind, placebo-controlled, randomized crossover study, disease-free patients at least 1 year postresection and gastric conduit reconstruction received either 1âmL 0.9% saline or 1âmL (100âµg) octreotide acetate subcutaneously followed by a standardized ad libitum meal on each of two assessments. Fasting and postprandial plasma glucagon-like peptide 1 (GLP-1), peptide YY (PYY), and ghrelin immunoreactivity were measured. Gut hormone responses and calorie intake postsaline versus octreotide were compared between experimental and control groups. RESULTS: Eighteen subjects [esophagectomy (ES), nâ=â10, 2.4â±â0.75 years postresection; and unoperated control subjects, nâ=â8] were studied. ES demonstrated significant weight loss at 3, 6, 12, and 24 months postoperatively (all Pâ<â0.05). Ghrelin levels were similar (Pâ=â0.58) for both groups, but postprandial GLP-1 and PYY responses were significantly (Pâ<â0.001) greater among ES as compared with controls. After octreotide, ad libitum calorie intake increased among ES (1.5â±â0.2 fold-change, Pâ=â0.02) but not controls (1.1â±â0.1 fold-change, Pâ=â0.30). CONCLUSIONS: ES demonstrated an exaggerated postprandial satiety gut hormone response that was attenuated by octreotide, thus identifying a potential therapeutic target to modulate in the ES patient with early satiety.